• NuWays reiterated a BUY rating on Limes Schlosskliniken, keeping its 12-month target price at EUR 810.
• H1 sales rose 29.2% to EUR 29.7 million, driven by 31,552 billed patient days, up 17.5%.
• EBITDA increased 12% to EUR 7 million; margin slipped to 23.6% as new clinics ramped up.
• Free cash flow swung to EUR 4.8 million from EUR -0.7 million, reflecting lower capex and stronger operating cash flow.
• NuWays highlighted faster break-even at new sites; it expects rising cash generation as occupancy scales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Limes Schlosskliniken AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26694) on September 01, 2026, and is solely responsible for the information contained therein.